Hippocampal serotonergic system is involved in anxiety-like behavior induced by corticotropin-releasing factor

Brain Research

Volumn 991, Issue 1-2, 2003, Pages 212-221

  Kagamiishi, Yoshifumi ^a,b   Yamamoto, Tsuneyuki ^a   Watanabe, Shigenori ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b ONO PHARMACEUTICAL CO   (Japan)

Author keywords

5 HT1A receptor agonist; Anxiety; Brain microdialysis; Corticotropin releasing factor; Hippocampus; Serotonin

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR[9-41]; SEROTONIN 1A AGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; BEHAVIOR DISORDER; BRAIN REGION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEPRESSION; DIALYSIS; DRUG EFFECT; HIPPOCAMPUS; HORMONE ACTION; HYPOTHESIS; IN VIVO STUDY; MALE; MAZE TEST; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION; TASK PERFORMANCE; TECHNIQUE;

EID: 0142090723     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2003.08.021     Document Type: Article

References (70)

1. Boadle-Biber M.C., Singh V.B., Corley K.C., Hao-Phan T., Dilts R.P. Evidence that corticotropin-releasing factor within the extended amygdala mediates the activation of tryptophan hydroxylase produced by sound stress in the rat. Brain Res. 628:1993;105-114.
2. Brauns O., Liepold T., Radulovic J., Spiess J. Pharmacological and chemical properties of astressin, antisauvagine-30 and alpha-hel CRF: significance for behavioral experiments. Neuropharmacology. 41:2001;507-516.
3. Bremner J.D., Lucinio J., Darnell A., Krystal J.H., Owens M.J., Southwick S.M., Nemeroff C.B., Charney D.S. Elevated CSF corticotropin- releasing factor concentrations in posttraumatic stress disorder. Am. J. Psychiatry. 154:1997;624-629.
4. Buwalda B., de Boer S.F., Van Kalkeren A.A., Koolhaas J.M. Physiological and behavioral effects of chronic intracerebroventricular infusion of corticotropin-releasing factor in the rat. Psychoneuroendocrinology. 22:1997;297-309.
5. 1A receptor agonist BAY×3702 on serotonergic cell firing and release. Naunyn-Schmiedeberg's Arch. Pharmacol. 362:2000;248-254.
6. Cole B.J., Koob G.F. Propranolol antagonizes the enhanced conditioned fear produced by corticotropin releasing factor. J. Pharmacol. Exp. Ther. 247:1988;902-910.
7. 1A antagonist, WAY100635. Psychopharmacology (Berl.). 132:1997;35-43.
8. Curtis A.L., Grigoriadis D.E., Page M.E., Rivier J., Valentino R.J. Pharmacological comparison of two corticotropin-releasing factor antagonists: in vivo and in vitro studies. J. Pharmacol. Exp. Ther. 268:1994;359-365.
9. Curtis A.L., Lechner S.M., Pavcovich L.A., Valentino R.J. Activation of the locus coeruleus noradrenergic system by intracoerulear microinjection of corticotrotropin-releasing factor: effects on discharge rate, cortical norepinephrine levels and cortical electroencephalographic activity. J. Pharmacol. Exp. Ther. 281:1997;163-172.
10. Deacon R.M., Bannerman D.M., Rawlins J.N. Anxiolytic effects of cytotoxic hippocampal lesions in rats. Behav. Neurosci. 116:2002;494-497.
11. den Boer J.A., Westenberg H.G.M. Involvement of serotonin receptor subtypes in panic disorder. Westenberg H.G.M., den Boer J.A., Murphy D.L. Advances in the Neurobiology of Anxiety Disorders. 1996;139-172 Wiley, Chichester.
12. Diamant M., Croiset G., De Weid D. The effect of corticotropin-releasing factor (CRF) on autonomic and behavioral responses during shock-probe burying test in rats. Peptides. 13:1992;1149-1158.
13. Feighner J.P., Boyer W.F. Serotonin-1A anxiolytics: an overview. Psychopathology. 22(Suppl. 1):1989;21-26.
14. File S.E., Zangrossi H.J., Andrews N. Novel environment and cat odor change GABA and 5-HT release and uptake in the rat. Pharmacol. Biochem. Behav. 45:1993;931-934.
15. 1A receptor modulation of anxiety in two ethological animal tests. J. Neurosci. 16:1996;4810-4815.
16. Gray J.A. Precis of the neuropsychology of anxiety: an enquiry into the functions of the septo-hippocampal system. Behav. Brain Sci. 5:1982;469-534.
17. Griebel G., Perrault G., Sanger D.J. Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone. Psychopharmacology (Berl.). 138:1998;55-66.
18. Griebel G., Simiand J., Steinberg R., Jung M., Gully D., Roger P., Geslin M., Scatton B., Maffrand J.P., Soubrie P. 4-(2-Chloro-4-methoxy-5- methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl] 5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist: II. Characterization in rodent models of stress-related disorders. J. Pharmacol. Exp. Ther. 301:2002;333-345.
19. Gutman D.A., Owens M.J., Skelton K.H., Thrivikraman K.V., Nemeroff C.B. The corticotropin-releasing factor1 receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress. J. Pharmacol. Exp. Ther. 304:2003;874-880.
20. Handley S.L., McBlane J.W. 5-HT drugs in animal models of anxiety. Psychopharmacology. 112:1993;13-20.
21. Handley S.L., McBlane J.W., Critchley M.A., Njung'e K. Multiple serotonin mechanisms in animal models of anxiety: environmental, emotional and cognitive factors. Behav. Brain Res. 58:1993;203-210.
22. Heinrichs S.C., Pich E.M., Miczek K., Britton K.T., Koob G.F. Corticotropin-releasing factor antagonist reduces emotionality in socially defeated rats via direct neurotropic action. Brain Res. 581:1992;190-197.
23. Heinrichs S.C., Menzaghi F., Merlo-Pich E., Baldwin H.A., Rassnick S., Britton K.T., Koob G.F. Anti-stress action of a corticotropin-releasing factor antagonist on behavioral reactivity to stressors of varying type and intensity. Neuropsychopharmacology. 11:1994;179-186.
24. 1A agonistic anxiolytic. Neuropharmacology. 30:1991;475-480.
25. Kawahara H., Yoshida M., Yokoo H., Nishi M., Tanaka M. Psychological stress increases serotonin release in the rat amygdala and prefrontal cortex assessed by in vivo microdialysis. Neurosci. Lett. 162:1993;81-84.
26. 1 receptor antagonists for the treatment of anxiety, depression and stress disorders. Curr. Drug Target CNS Neurol. Disord. 1:2002;467-493.
27. 1A presynaptic, but not postsynaptic receptor-mediated responses: relationship to antidepressant-like action. Eur. J. Pharmacol. 138:1987;53-60.
28. 1C receptor antagonists. Eur. J. Pharmacol. 164:1989;445-454.
29. Kirby L.G., Rice K.C., Valentino R.J. Effects of corticotropin-releasing factor on neuronal activity in the serotonergic dorsal raphe nucleus. Neuropsychopharmacology. 22:1999;148-162.
30. Klint T. Effects of 8-OH-DPAT and buspirone in a passive avoidance test and in the elevated plus-maze test in rats. Behav. Pharmacol. 2:1991;481-489.
31. Koob G.F. Corticotropin-releasing factor, norepinephrine, and stress. Biol. Psychiatry. 46:1999;1167-1180.
32. Lavicky J., Dunn A.J. Corticotropin-releasing factor stimulates catecholamine release in hypothalamus and prefrontal cortex in freely moving rats as assessed by microdialysis. J. Neurochem. 60:1993;602-612.
33. Lundkvist J., Chai Z., Teheranian R., Hasanvan H., Bartfai T., Jenck F., Widmer U., Moreau J.L. A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity. Eur. J. Pharmacol. 309:1996;195-200.
34. Marsden C.A. The pharmacology of new anxiolytics acting on 5-HT neurones. Postgrad. Med. J. 66(Suppl. 2):1990;S2-S6.
35. Menzaghi F., Howard R.L., Heinrichs S.C., Vale W., Rivier J., Koob G.F. Characterization of a novel and potent corticotropin-releasing factor antagonist in rats. J. Pharmacol. Exp. Ther. 269:1994;564-572.
36. 1 antagonists, CP154,526 and DMP695: a comparison to other classes of anxiolytic agent. Neuropsychopharmacology. 25:2001;585-600.
37. Nemeroff C.B., Widerlov E., Bissette G., Walleus H., Karlsson I., Eklund K., Kilts C.D., Loosen P.T., Vale W. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science. 226:1984;1342-1344.
38. 1A receptors in animal tests of anxiety and depression: evidence from genetic models. Stress. 6:2003;101-110.
39. Owens M.J., Nemeroff C.B. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol. Rev. 43:1991;425-473.
40. Owens M.J., Nemeroff C.B. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin. Chem. 40:1994;288-295.
41. Parks C.L., Robinson P.S., Sibille E., Shenk T., Toth M. Increased anxiety of mice lacking the serotonin1A receptor. Proc. Natl. Acad. Sci. U. S. A. 95:1998;10734-10739.
42. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic Press, Sydney.
43. Pecknold J.C., Matas M., Howarth B.G., Ross C., Swinson R., Vezeau C., Ungar W. Evaluation of buspirone as an antianxiety agent: buspirone and diazepam versus placebo. Can. J. Psychiatry. 34:1989;766-771.
44. 2 receptors in behavioral, but not endocrine, response to environmental stress. J. Pharmacol. Exp. Ther. 302:2002;145-152.
45. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods. 14:1985;149-167.
46. Pigott T.A., Hill J.L., Grady T.A., L'Heureux F., Berstein S., Rubinstein C.S., Murphy D.L. A comparison of the behavioural effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP. Biol. Psychiatry. 33:1993;3-14.
47. Potter E., Sutton S., Donaldson C., Chen R., Perrin M., Lewis K., Sawchenko P.E., Vale W. Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary. Proc. Natl. Acad. Sci. U. S. A. 91:1994;8777-8781.
48. Price M.L., Lucki I. Regulation of serotonin release in the lateral septum and striatum by corticotropin-releasing factor. J. Neurosci. 21:2001;2833-2841.
49. Rex A., Fink H., Marsden C.A. Effects of BOC-CCK-4 and L-365,260 on cortical 5-HT release in guinea-pigs on exposure to the elevated plus maze. Neuropharmacology. 33:1994;559-565.
50. 1A agonist, in three stress paradigms: immobilization, forced swim and conditioned fear. Brain Res. 580:1992;205-214.
51. 1 antagonists on social interaction in rats. Soc. Neurosci. Abstr. 22:1996;1544.
52. Sakurai-Yamashita Y., Kataoka Y., Yamashita K., Miyazaki A., Ushio M., Mine K., Niwa M., Ueki S. Conflict behavior and dynamics of monoamines of various brain nuclei in rats. Neuropharmacology. 28:1989;1067-1073.
53. Sarnyai Z., Biro E., Gardi J., Vecsernyes M., Julesz J., Telegdy G. Brain corticotropin-releasing factor mediates 'anxiety-like' behavior induced by cocaine withdrawal in rats. Brain Res. 675:1995;89-97.
54. 1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br. J. Pharmacol. 96:1989;283-290.
55. Sherman J.E., Kalin N.H. ICV-CRH alters stress-induced freezing behavior without affecting pain sensitivity. Pharmacol. Biochem. Behav. 30:1988;801-807.
56. Smagin G.N., Swiergiel A.H., Dunn A.J. Corticotropin-releasing factor administered into the locus coeruleus, but not the parabrachial nucleus, stimulates norepinephrine release in the prefrontal cortex. Brain Res. Bull. 36:1995;71-76.
57. 1A receptor agonist, buspirone, after prolonged chronic administration. Eur. J. Pharmacol. 239:1993;69-73.
58. 1B agonists: a comparative study with dorsal raphe neurons. Neuropharmacology. 27:1988;707-715.
59. Stout S.C., Owens M.J., Nemeroff C.B. Regulation of corticotropin- releasing factor neuronal systems and hypothalamic-pituitary-adrenal axis activity by stress and chronic antidepressant treatment. J. Pharmacol. Exp. Ther. 300:2002;1085-1092.
60. Swanson L.W., Sawchenko P.E., Rivier J., Vale W.W. Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology. 36:1983;165-186.
61. Swerdlow N.R., Geyer M.A., Vale W.W., Koob G.F. Corticotropin-releasing factor potentiates acoustic startle in rats: blockade by chlordiazepoxide. Psychopharmacology. 88:1986;147-152.
62. 9-41. Neuropsychopharmacology. 2:1989;285-292.
63. Vahabzadeh A., Fillenz M. Comparison of stress-induced changes in noradrenergic and serotonergic neurons in the rat hippocampus using microdialysis. Eur. J. Neurosci. 6:1994;1205-1212.
64. Vale W., Spiess J., Rivier C., Rivier J. Characterization of a 41 residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta endorphin. Science. 213:1981;1394-1397.
65. Valentino R.J., Foote S.L., Aston-Jones G. Corticotropin-releasing factor activates noradrenergic neurons of the locus coeruleus. Brain Res. 270:1983;363-377.
66. Vaughan J., Donaldson C., Bittencourt J., Perrin M.H., Lewis K., Sutton S., Chan R., Turnbull A.V., Lovejoy D., Rivier C., Sawchenko P.E., Vale W. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature. 378:1995;287-292.
67. Wright I.K., Upton N., Marsden C.A. Effect of established and putative anxiolytics on extracellular 5-HT and 5-HIAA in the ventral hippocampus of rats during behaviour on the elevated X-maze. Psychopharmacology. 109:1992;338-346.
68. Yoshioka M., Matsumoto M., Togashi H., Saito H. Effects of conditioned fear stress on 5-HT release in the rat prefrontal cortex. Pharmacol. Biochem. Behav. 51:1995;515-519.
69. Zobel A.W., Nickel T., Künzel H.E., Ackl N., Sonntag A., Ising M., Holsboer F. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res. 34:2000;171-181.
70. Zorrilla E.P., Valdez G.R., Nozulak J., Koob G.F., Markou A. Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. Brain Res. 952:2002;188-199.